C4 Therapeutics Inc (NASDAQ:CCCC) shares, rose in value on Tuesday, December 31, with the stock price down by -1.10% to the previous day’s close as strong demand from buyers drove the stock to $3.60.
Actively observing the price movement in the last trading, the stock closed the session at $3.64, falling within a range of $3.43 and $3.695. The value of beta (5-year monthly) was 3.056. Referring to stock’s 52-week performance, its high was $11.88, and the low was $3.53. On the whole, CCCC has fluctuated by -20.88% over the past month.
With the market capitalization of C4 Therapeutics Inc currently standing at about $251.33 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 4.33M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CCCC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CCCC currently trading nearly -11.08% and -24.52% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.78, while the 7-day volatility ratio is showing 8.29% which for the 30-day chart, stands at 10.11%. Furthermore, C4 Therapeutics Inc (CCCC)’s beta value is 2.97, and its average true range (ATR) is 0.38.
A comparison of C4 Therapeutics Inc (CCCC) with its peers suggests the former has fared considerably weaker in the market. CCCC showed an intraday change of -1.10% in last session, and over the past year, it shrunk by -36.28%%.
Data on historical trading for C4 Therapeutics Inc (NASDAQ:CCCC) indicates that the trading volumes over the past 10 days have averaged 2.03 and over the past 3 months, they’ve averaged 1.27 million. According to company’s latest data on outstanding shares, there are 70.56 million shares outstanding.
Nearly 19.37% of C4 Therapeutics Inc’s shares belong to company insiders and institutional investors own 83.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.87 million shares as on 2024-12-13, resulting in a short ratio of 5.61. According to the data, the short interest in C4 Therapeutics Inc (CCCC) stood at 1522.00 of shares outstanding as of 2024-12-13; the number of short shares registered in 2024-11-15 reached 7.4 million. The stock has fallen by -36.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CCCC stock heading into the next quarter.
